Literature DB >> 3981615

Crossreactivity of antiphospholipid antibodies.

E N Harris, A E Gharavi, S Loizou, G Derue, J K Chan, B M Patel, C G Mackworth-Young, C C Bunn, G R Hughes.   

Abstract

Using a solid phase radioimmunoassay to detect anticardiolipin antibodies, the crossreactivity of these antibodies with phospholipids and DNA was tested in 10 patients with autoimmune disorders and 1 patient with secondary syphilis. The crossreactivity of anti-ds DNA and anti-ss DNA antibodies with cardiolipin was tested in 10 additional patients with SLE. In the 10 sera tested with high anticardiolipin antibody levels, there was marked inhibition of anticardiolipin antibody activity by negatively charged phospholipids. The zwitterionic phospholipids inhibited anticardiolipin antibody activity in some sera, and in instances where this occurred, inhibition was less than that obtained for the negatively charged phospholipids. There was minimal inhibition of anticardiolipin antibody by ss DNA in only 2 of 10 sera tested and no inhibition by ds DNA in any sera tested. Conversely, cardiolipin inhibited anti-ss DNA antibody activity in 2 of 10 sera, and anti-ds DNA antibody activity in 2 of 10 sera tested. There was no correlation between anticardiolipin antibody levels and either anti-ds DNA or anti-ss DNA antibody levels. These results suggest that antiphospholipid and anti-DNA antibodies are largely separate groups of antibodies. On the basis of these studies, we suggest that there may be various groups of antiphospholipid antibodies in patients with SLE and other autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981615

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  29 in total

1.  Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies.

Authors:  M Sorice; A Circella; R Misasi; V Pittoni; T Garofalo; A Cirelli; A Pavan; G M Pontieri; G Valesini
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  [Female patient with Sjoegren's syndrome and cardiolipin antibodies].

Authors:  S Vilardi; K Muth; M Uppenkamp; R Bergner
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

Review 3.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  IgG anti-cardiolipin antibodies in murine lupus.

Authors:  A E Gharavi; R C Mellors; K B Elkon
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

5.  Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies.

Authors:  R A Fields; W L Sibbitt; H Toubbeh; A D Bankhurst
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

6.  Anti-Klebsiella K30 phospholipid antibodies in systemic lupus erythematosus: antigen cross-reactions and idiotypic sharing with antibodies to DNA and Klebsiella K30 polysaccharide.

Authors:  G D Harkiss; F M Hendrie; D Thompson
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

Review 7.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients.

Authors:  Roozbeh Jamshid; Serati Ali Reza; Ghaderi Abbas; Afshariani Raha
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

9.  Antiphospholipid antibodies in systemic lupus erythematosus: clinical and laboratory associations in 111 patients.

Authors:  Y Wang; L Schrieber; M G Cohen; L Furphy; J Webb; T Chivers; K M Pollard
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

Authors:  A E Gharavi; L R Sammaritano; J Wen; K B Elkon
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.